Compare ACON & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACON | PMCB |
|---|---|---|
| Founded | 2008 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 6.3M |
| IPO Year | 2022 | 2001 |
| Metric | ACON | PMCB |
|---|---|---|
| Price | $2.35 | $0.55 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 41.1K | ★ 125.6K |
| Earning Date | 05-15-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.82 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $75,730.00 | N/A |
| Revenue This Year | $87.22 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 65.62 | N/A |
| 52 Week Low | $1.95 | $0.53 |
| 52 Week High | $12.03 | $1.51 |
| Indicator | ACON | PMCB |
|---|---|---|
| Relative Strength Index (RSI) | 43.43 | 35.67 |
| Support Level | $1.95 | $0.55 |
| Resistance Level | $2.50 | $0.77 |
| Average True Range (ATR) | 0.18 | 0.04 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 72.73 | 31.02 |
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.